InvestorsHub Logo
Followers 16
Posts 5825
Boards Moderated 0
Alias Born 07/16/2018

Re: LaurieM post# 16167

Wednesday, 06/10/2020 12:50:52 PM

Wednesday, June 10, 2020 12:50:52 PM

Post# of 21540
IS THE "PLANNED" P3 GOING TO START ENROLLING BEFORE, DURING, OR AFTER THE "New Phase 2 Study to Evaluate Long-Term Therapeutic Effect of Bryostatin-1 in AD"??????????


https://ih.advfn.com/stock-market/NASDAQ/neurotrope-NTRP/stock-news/82552783/neurotrope-launches-new-long-term-clinical-trial-o


NEW YORK, May 28, 2020 /PRNewswire/ -- Neurotrope, Inc. (Nasdaq: NTRP) today announced the launch of a new long-term study of Bryostatin-1 for the treatment of patients with Alzheimer's disease (AD). The Phase 2 clinical study will be conducted in collaboration with the National Institutes of Health (NIH) under a $2.7 million grant to Neurotrope. After reviewing the data from the previous trial with Key Opinion Leaders and the NIH, we designed a study to evaluate the long-term therapeutic effect of Bryostatin-1 in the absence of Namenda® (memantine) in patients with AD. The Company has engaged Worldwide Clinical Trials to initiate site recruitment and activation.

Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent SNPX News